Syndax Announces Participation at Two Upcoming Investor Conferences

WALTHAM, Mass., Feb. 26, 2024

• A fireside chat at TD Cowen's 44^th Annual Health Care Conference at 9:50 a.m. ET on Monday, March 4, 2024 in Boston, MA
• A corporate panel discussion on leukemia at TD Cowen's 44^th Annual Health Care Conference at 12:50 p.m. ET on Monday, March 4, 2024 in Boston, MA
• A fireside chat at the Barclays Global Healthcare Conference at 8:30 a.m. ET on Tuesday, March 12, 2024 in Miami, FL

A live webcast of these sessions can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.

Syndax Contacts

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G